These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 32274678)

  • 1. Adverse Changes in HbA1c, Body Weight and Insulin Use in People with Type 1 Diabetes Mellitus Following Dapagliflozin Discontinuation in the DEPICT Clinical Trial Programme.
    Gordon J; Danne T; Beresford-Hulme L; Bennet H; Tank A; Edmonds C; Thorén F; Scheerer MF; McEwan P
    Diabetes Ther; 2020 May; 11(5):1135-1146. PubMed ID: 32274678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefit/risk profile of dapagliflozin 5 mg in the DEPICT-1 and -2 trials in individuals with type 1 diabetes and body mass index ≥27 kg/m
    Mathieu C; Dandona P; Birkenfeld AL; Hansen TK; Iqbal N; Xu J; Repetto E; Scheerer MF; Thoren F; Phillip M
    Diabetes Obes Metab; 2020 Nov; 22(11):2151-2160. PubMed ID: 32691513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Effectiveness and Impact on Insulin Therapy Cost After Addition of Dapagliflozin to Patients with Uncontrolled Type 2 Diabetes.
    Sosale B; Sosale A; Bhattacharyya A
    Diabetes Ther; 2016 Dec; 7(4):765-776. PubMed ID: 27761881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT-5): 52-week results from a randomized, open-label, phase III clinical trial.
    Araki E; Watada H; Uchigata Y; Tomonaga O; Fujii H; Ohashi H; Okabe T; Asano M; Thoren F; Kim H; Yajima T; Langkilde AM
    Diabetes Obes Metab; 2020 Apr; 22(4):540-548. PubMed ID: 31742898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of dapagliflozin as an adjunct to insulin for the treatment of type 1 diabetes mellitus in the United Kingdom.
    Bennett H; Tank A; Evans M; Bergenheim K; McEwan P
    Diabetes Obes Metab; 2020 Jul; 22(7):1047-1055. PubMed ID: 32037675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between hypoglycaemia, body mass index and quality of life among patients with type 1 diabetes: Observations from the DEPICT clinical trial programme.
    Gordon J; Beresford-Hulme L; Bennett H; Tank A; Edmonds C; McEwan P
    Diabetes Obes Metab; 2020 May; 22(5):857-865. PubMed ID: 31970881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dapagliflozin as an Adjunct Therapy to Insulin in Patients with Type 1 Diabetes Mellitus: Efficacy and Safety of this Combination.
    Jendle JH; Ampudia-Blasco FJ; Füchtenbusch M; Pozzilli P
    touchREV Endocrinol; 2021 Apr; 17(1):12-20. PubMed ID: 35118442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycated Hemoglobin, Body Weight and Blood Pressure in Type 2 Diabetes Patients Initiating Dapagliflozin Treatment in Primary Care: A Retrospective Study.
    Wilding J; Bailey C; Rigney U; Blak B; Beekman W; Emmas C
    Diabetes Ther; 2016 Dec; 7(4):695-711. PubMed ID: 27585582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea.
    Han E; Kim A; Lee SJ; Kim JY; Kim JH; Lee WJ; Lee BW
    Diabetes Ther; 2018 Aug; 9(4):1689-1701. PubMed ID: 29998370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dapagliflozin: an effective adjunctive treatment in type 1 diabetes.
    Yadegarfar G; Livingston M; Cortes G; Alshames R; Leivesley K; Metters A; Horne L; Steele T; Heald AH
    Cardiovasc Endocrinol Metab; 2021 Jun; 10(2):132-136. PubMed ID: 34124604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of dapagliflozin as an insulin adjunct in type 1 diabetes: a semi-mechanistic exposure-response model.
    Sokolov V; Yakovleva T; Penland RC; Boulton DW; Tang W
    Front Pharmacol; 2023; 14():1229255. PubMed ID: 37954838
    [No Abstract]   [Full Text] [Related]  

  • 12. Associations of Plasma Concentration Profiles of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-Transporter Type 2, with Its Effects in Japanese Patients with Type 2 Diabetes Mellitus.
    Hayakawa T; Kato KI; Kobuchi S; Kataoka K; Sakaeda T
    Pharmaceuticals (Basel); 2022 Feb; 15(2):. PubMed ID: 35215315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use and effectiveness of dapagliflozin in patients with type 2 diabetes mellitus: a multicenter retrospective study in Taiwan.
    Chen JF; Peng YS; Chen CS; Tseng CH; Chen PC; Lee TI; Lu YC; Yang YS; Lin CL; Hung YJ; Chen ST; Lu CH; Yang CY; Chen CC; Lee CC; Hsiao PJ; Jiang JY; Tu ST
    PeerJ; 2020; 8():e9998. PubMed ID: 33240585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study).
    Nakajima H; Okada S; Mohri T; Kanda E; Inaba N; Hirasawa Y; Seino H; Kuroda H; Hiyoshi T; Niiya T; Ishii H
    Diabetol Metab Syndr; 2018; 10():11. PubMed ID: 29507611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes.
    Evans M; Hicks D; Patel D; Patel V; McEwan P; Dashora U
    Diabetes Ther; 2020 Jan; 11(1):37-52. PubMed ID: 31813092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus in Saudi Arabia: A Post Authorization Safety Study.
    Alguwaihes AM
    Diabetes Ther; 2021 Jul; 12(7):1979-1992. PubMed ID: 34118010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy: a primary care database study.
    Scheerer MF; Rist R; Proske O; Meng A; Kostev K
    Diabetes Metab Syndr Obes; 2016; 9():337-345. PubMed ID: 27822077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality-of-Life Comparison of Dapagliflozin Versus Dipeptidyl Peptidase 4 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial (J-BOND Study).
    Ishii H; Nakajima H; Kamei N; Niiya T; Hiyoshi T; Hiramori Y; Ohtsu S; Noto T; Shimono D
    Diabetes Ther; 2020 Dec; 11(12):2959-2977. PubMed ID: 33057967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study Protocol for the Effects of Formula Diet with Dapagliflozin on Metabolic Improvement and Body Composition in Type 2 Diabetes Mellitus.
    Watanabe Y; Kuribayashi N; Uchida D; Suzuki D; Kato M; Nagayama D; Ohashi H; Ohira M; Saiki A; Tatsuno I
    Diabetes Ther; 2019 Feb; 10(1):311-321. PubMed ID: 30574667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus.
    Tamez HE; Tamez AL; Garza LA; Hernandez MI; Polanco AC
    J Diabetes Metab Disord; 2015; 14():78. PubMed ID: 26457255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.